Quantum Drug Discovery and the Path to Advantage with Sabrina Maniscalco

What does it actually take to run a quantum-classical workflow on a real cancer drug — not hydrogen, not a toy molecule, but a photosensitizer already in Phase II clinical trials? Sabrina Maniscalco, CEO and co-founder of Algorithmiq, joins Sebastian to unpack the science behind the company's Wellcome Leap Q4Bio win, its €18M raise, and its move from Helsinki to Milan. Along the way: error mitigation, tensor networks, sampling tradeoffs across hardware platforms, and an honest look at where quantum advantage in chemistry might actually land.